Search results
AbbVie Reports First-Quarter 2024 Financial Results
The Belmond Independent· 6 days agoReports First-Quarter Diluted EPS of $0.77 on a GAAP Basis, an Increase of 492.3 Percent; Adjusted Diluted EPS of $2.31, a Decrease of 6.1 Percent; These Results Include an Unfavorable
AbbVie (ABBV) Reports Q1 Earnings: What Key Metrics Have to Say
Zacks via Yahoo Finance· 6 days agoWhile the top- and bottom-line numbers for AbbVie (ABBV) give a sense of how the business performed...
AbbVie Lifts Outlook After 1Q Revenue Unexpectedly Rises
Morningstar· 6 days agoBy Dean Seal AbbVie raised its annual adjusted earnings guidance after revenue unexpectedly rose in the first quarter as lower sales of Humira were offset with gains elsewhere ...
AbbVie tries to reassure investors on Humira biosimilar threat
BioPharma Dive via Yahoo Finance· 6 days agoDive Brief: U.S. Humira sales fell 40% year over year during the first three months of 2024, to...
AbbVie Stock Falls As Company Warns of Continued Humira Sales Slump
Investopedia· 6 days agoShares of AbbVie (ABBV) slumped Friday as the pharmaceutical firm warned of deeper declines in sales...
AbbVie: Q1 Earnings Snapshot
Midland Reporter-Telegram· 6 days agoNORTH CHICAGO, Ill. (AP) — NORTH CHICAGO, Ill. (AP) — AbbVie Inc. (ABBV) on Friday...
AbbVie hikes 2024 earnings guidance as Q1 beat estimates, shares up By Investing.com
Investing.com· 6 days agoAbbVie hikes 2024 earnings guidance as Q1 beat estimates, shares up
3 Dividend Stocks to Buy and Hold for the Next Decade
Motley Fool via Yahoo Finance· 5 days agoYou only have to find the right stocks worthy of holding for the long term and that pay attractive...
AbbVie hikes 2024 earnings guidance as Q1 beat estimates, shares up
Investing.com· 6 days agoAbbVie hikes 2024 earnings guidance as Q1 beat estimates, shares up
AbbVie Lifts 2024 Forecast as Newer Drugs Replace Humira Losses
Bloomberg· 6 days agoAbbVie Inc. lifted its full-year profit guidance as newer anti-inflammatory treatments like Rinvoq...
